Speaking at Thoracic Society of Australia and New Zealand (TSANZ) 2024 annual meeting, Professor Kwun Fong spoke about some of the ‘new kids on the block’ when it comes to blood-based proteomic and genomic biomarkers for lung cancer. Techniques such as polygenic risk scores and liquid biopsies will be able to inform prevention, early detection and even screening of lung cancer, he says. And Professor Ken O’Byrne explained how proteomics and genomic developments are influencing the treatment of lung cancer.